viii
11 Biologic Therapy in Pediatric Inflammatory Bowel Disease........ 163
Sonal Patel and Jennifer Strople
12 Infectious Complications of Biologics........................... 185
Renée M. Marchioni Beery and Joshua R. Korzenik
13 Tumor Necrosis Factor-Alpha Inhibitors
and Risks of Malignancy..................................... 213
Julia T. Hughes and Millie D. Long
14 Noninfectious and Nonmalignant Complications
of Anti-TNF Therapy........................................ 231
Uni Wong and Raymond K. Cross
15 Biosimilars in Inflammatory Bowel Disease 2017: State
of the Science, State of the Art, and State of the Finances.......... 261
Christina Y. Ha and Asher Kornbluth
16 Anti-integrin Agents in IBD: Efficacy and Risk of Complications.... 283
Jimmy K. Limdi and Francis A. Farraye
17 Novel Agents in Inflammatory Bowel Disease.................... 303
Fernando Velayos
18 Quality, Safety, and Practical Considerations of Using
Biologic Therapies........................................... 315
Leilei Zhu and Gil Y. Melmed
Index......................................................... 329
Contents